Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 839 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: EGFR Clear all

Conditions: High Grade Glioma, Glioblastoma
Interventions: BDTX-1535, BDTX-1535 combined with radiation therapy, BDTX-1535 combined with temozolomide and radiation therapy; Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Chandler, Arizona • Phoenix, Arizona

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: erlotinib hydrochloride, docetaxel, radiation therapy, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study; Drug · Radiation · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Neoplasms, Breast Cancer, Cancer of the Breast
Interventions: Lapatinib and Everolimus; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Metastatic Breast Cancer
Interventions: lapatinib; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 3
States / cities: Kansas City, Kansas • Topeka, Kansas • Kansas City, Missouri

Conditions: Metastatic Non Small Cell Lung Cancer
Interventions: APL-101, Osimertinib; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 23
States / cities: Bellflower, California • Fullerton, California • La Jolla, California + 19 more

Conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Interventions: AUY922, Cetuximab; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab, Targeted Molecular Therapy, Tyrosine Kinase Inhibitor; Drug · Biological · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Neoplasms, Tumors, Solid Tumors, Metastatic Cancer
Interventions: EGFRBi-armed autologous activated T cells; Biological
Lead sponsor: Roger Williams Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: PF-3512676 + Erlotinib, Erlotinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 35
States / cities: Daphne, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more

Conditions: Lung Adenocarcinoma, Lung Neoplasms
Interventions: osimertinib, Local Ablative Therapy (LAT); Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo; Drug
Lead sponsor: Bicara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 55
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 41 more

Conditions: Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline, Pancreatic Cancer Resectable
Interventions: ASP-1929 photoimmunotherapy; Combination Product
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Osimertinib, Positron Emission Tomography, Telaglenastat Hydrochloride, X-Ray Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 11
States / cities: Birmingham, Alabama • Coral Gables, Florida • Deerfield Beach, Florida + 8 more

Conditions: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma Cancer, Metastatic Gastric Adenocarcinoma Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Interventions: zolbetuximab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Dose escalation followed by treatment with MTD; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Aurora, Colorado • Boston, Massachusetts

Conditions: Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer, Colorectal Carcinoma, Recurrent Ovarian Carcinoma, BRAF-Mutated Melanoma
Interventions: TP-0903; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 16
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Denver, Colorado + 12 more

Conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROSE Cluster 1, BRAF V600E
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Advanced EGFR Positive Solid Tumor
Interventions: ZZ06; Biological
Lead sponsor: Changchun Intellicrown Pharmaceutical Co. LTD; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Los Angeles, California • Fairway, Kansas • The Bronx, New York

Conditions: Head and Neck Cancer
Interventions: Erlotinib, Celecoxib; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Gastric Cancer, Precancerous Condition
Interventions: Cetuximab; Biological
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Metastatic Triple Negative Breast Cancer
Interventions: Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 20
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 17 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Alisertib, Osimertinib, Sapanisertib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Breast Cancer
Interventions: Lapatinib; Drug
Lead sponsor: Gary Schwartz; Other
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Aurora, Colorado • Lebanon, New Hampshire • Lake Success, New York

Search by objective public record fields.

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors

Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Early Access Program for Zolbetuximab

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies

Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2

Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy